Maladaptive Myocardium and Heart Failure

kardiyoloji-15-5-kitap-kapak

Selda MURATa, Muhammet DURALa, Yüksel ÇAVUŞOĞLUa

aEskisehir Osmangazi University Faculty of Medicine, Department of Cardiology, Eskişehir, Türkiye

ABSTRACT
Heart failure is a major cause of morbidity and mortality among cardiovascular diseases. Heart failure is not an only pathological diagnosis, but a complex clinical syndrome resulting from structural and functional abnormalities that results in impairment of ventricular filling or ejection of ventricular volume. A variety of interrelated structural and functional alterations occur during development to heart failure. Most changes can be compensatory, but cannot prevent cardiac dysfunction in the long run. Sustained abnormal volume and pressure overload induces maladaptation and cardiac remodeling, resulting in heart failure. However, development of normative changes in ventricular size and function gives rise to the concept of reverse remodeling. In this section, the maladaptive process in heart failure will be addressed.
Keywords: Heart failure; left ventricular hypertrophy; ventricular remodeling

Referanslar

  1. McDonagh ta, metra m, adamo m, gardner rS, baumbach a, böhm m, et al. 2021 eSc guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task Force for the diagnosis and treatment of acute and chronic heart failure of the european Society of cardiology (eSc) with the special contribution of the Heart Failure association (HFa) of the eSc. eur Heart j. 2021;42(36):3599-726. [Crossref]  [PubMed]
  2. Heidenreich pa, bozkurt b, aguilar d, allen la, byun jj, colvin mm, et al. 2022 aHa/acc/HFSa guideline for the management of Heart Failure: a report of the american college of cardiology/american Heart association joint committee on clinical practice guidelines. j am coll cardiol. 2022;79(17):e263-e421.
  3. Francis gS. pathophysiology of chronic heart failure. am j med. 2001;110 Suppl 7a:37-46. [Crossref]  [PubMed]
  4. Rüdebusch j, benkner a, poesch a, dörr m, Völker u, grube K, et al. dynamic adaptation of myocardial proteome during heart failure development. ploS one. 2017;12(10):e0185915. [Crossref]  [PubMed]  [PMC]
  5. Borlaug ba, paulus wj. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. eur Heart j. 2011;32(6):670-9. [Crossref]  [PubMed]  [PMC]
  6. McDiarmid aK, Swoboda pp, erhayiem b, bounford Ka, bijsterveld p, tyndall K, et al. myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. j am Heart assoc. 2020;9(1):e011521. [Crossref]  [PubMed]  [PMC]
  7. Tsuda t. clinical assessment of ventricular wall stress in understanding compensatory hypertrophic response and maladaptive ventricular remodeling. j cardiovasc dev dis. 2021;8(10):122. [Crossref]  [PubMed]  [PMC]
  8. Cohn jn. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. circ j. 1995;91(10):2504-7. [Crossref]  [PubMed]
  9. Mann dl. Stress-activated cytokines and the heart: from adaptation to maladaptation. annu rev physiol. 2003;65:81-101. [Crossref]  [PubMed]
  10. Cohn jn, Ferrari r, Sharpe n. cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. behalf of an International Forum on cardiac remodeling. j am coll cardiol. 2000;35(3):569-82. [Crossref]  [PubMed]
  11. Dorn gw 2nd, robbins j, Sugden pH. phenotyping hypertrophy: eschew obfuscation. circ res. 2003;92(11):1171-5. [Crossref]  [PubMed]
  12. Braunwald e. pathophysiology of heart failure. In: braunwald e, ed. Heart disease. 4th ed. philadelphia: Saunders; 1992. p.393.
  13. Sabbah Hn, goldstein S. Ventricular remodelling: consequences and therapy. eur Heart j. 1993;14 Suppl c:24-9. [Crossref]  [PubMed]
  14. Opie lH, commerford pj, gersh bj, pfeffer ma. controversies in ventricular remodelling. lancet. 2006;367(9507):356-67. [Crossref]  [PubMed]
  15. Radauceanu a, ducki c, Virion jm, rossignol p, mallat Z, mcmurray j, et al. extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. j card Fail. 2008;14(6):467-74. [Crossref]  [PubMed]
  16. Van dijk Sj, Hamdani n, Stienen gj, van der Velden j. myocardial adaptations in the failing heart: cause or consequence? j muscle res cell motil. 2008;29(6-8):159-62. [Crossref]  [PubMed]
  17. Burchfield jS, Xie m, Hill ja. pathological ventricular remodeling: mechanisms: part 1 of 2. circ j. 2013;128(4):388-400. [Crossref]  [PubMed]  [PMC]
  18. Fraccarollo d, galuppo p, bauersachs j. novel therapeutic approaches to post-infarction remodelling. cardiovasc res. 2012;94(2):293-303. [Crossref]  [PubMed]
  19. Pfeffer jm, pfeffer ma, Fletcher pj, braunwald e. progressive ventricular remodeling in rat with myocardial infarction. am j physiol. 1991;260(5 pt 2):H1406-14. [Crossref]  [PubMed]
  20. Pfeffer ma, pfeffer jm, Fishbein mc, Fletcher pj, Spadaro j, Kloner ra, et al. myocardial infarct size and ventricular function in rats. circ res. 1979;44(4):503-12. [Crossref]  [PubMed]
  21. Udelson je, Konstam ma. Ventricular remodeling fundamental to the progression (and regression) of heart failure. j am coll cardiol. 2011;57(13):1477-9. [Crossref]  [PubMed]
  22. Kubanek m, Sramko m, maluskova j, Kautznerova d, weichet j, lupinek p, et al. novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. j am coll cardiol. 2013;61(1):54- 63. [Crossref]  [PubMed]
  23. Maron bj, towbin ja, thiene g, antzelevitch c, corrado d, arnett d, et al. contemporary definitions and classification of the cardiomyopathies: an american Heart association Scientific Statement from the council on clinical cardiology, Heart Failure and transplantation committee; Quality of care and outcomes research and Functional genomics and translational biology Interdisciplinary working groups; and council on epidemiology and prevention. circ j. 2006;113(14):1807-16. [Crossref]  [PubMed]
  24. Tayal u, prasad SK. myocardial remodelling and recovery in dilated cardiomyopathy. jrSm cardiovasc dis. 2017;6:1-7. [Crossref]  [PubMed]  [PMC]
  25. Choi jo, Kim eY, lee gY, lee Sc, park Sw, Kim dK, et al. predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. circ j. 2013;77(2):462-9. [Crossref]  [PubMed]
  26. Owan te, Hodge do, Herges rm, jacobsen Sj, roger Vl, redfield mm. trends in prevalence and outcome of heart failure with preserved ejection fraction. n engl j med. 2006;355(3):251-9. [Crossref]  [PubMed]
  27. Melenovsky V, borlaug ba, rosen b, Hay I, Ferruci l, morell cH, et al. cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban baltimore community: the role of atrial remodeling/dysfunction. j am coll cardiol. 2007;49(2):198-207. [Crossref]  [PubMed]
  28. Borlaug ba. the pathophysiology of heart failure with preserved ejection fraction. nat rev cardiol. 2014;11(9):507-15. [Crossref]  [PubMed]
  29. Borlaug ba, olson tp, lam cS, Flood KS, lerman a, johnson bd, et al. global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. j am coll cardiol. 2010;56(11):845-54. [Crossref]  [PubMed]  [PMC]
  30. Aurigemma gp, Zile mr, gaasch wH. contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. circulation. 2006;113(2):296-304. [Crossref]  [PubMed]
  31. Aurigemma gp, gaasch wH. clinical practice. diastolic heart failure. n engl j med. 2004;351(11):1097-105. [Crossref]  [PubMed]
  32. Baicu cF, Zile mr, aurigemma gp, gaasch wH. left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. circ j. 2005;111(18):2306-12. [Crossref]  [PubMed]
  33. Borbély a, van der Velden j, papp Z, bronzwaer jg, edes I, Stienen gj, et al. cardiomyocyte stiffness in diastolic heart failure. circ j. 2005;111(6):774- 81. [Crossref]  [PubMed]
  34. Van Heerebeek l, borbély a, niessen Hw, bronzwaer jg, van der Velden j, Stienen gj, et al. myocardial structure and function differ in systolic and diastolic heart failure. circ j. 2006;113(16):1966-73. [Crossref]  [PubMed]
  35. persson H, lonn e, edner m, baruch l, lang cc, morton jj, et al. diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the cHarm echocardiographic SubstudycHarmeS. j am coll cardiol. 2007;49(6):687-94. [Crossref]  [PubMed]
  36. Lam cS, roger Vl, rodeheffer rj, bursi F, borlaug ba, ommen Sr, et al. cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from olmsted county, minnesota [published correction appears in circulation. 2007 may 22;115(20):e535]. circ j. 2007;115(15):1982-90. [Crossref]  [PubMed]  [PMC]
  37. Xie m, burchfield jS, Hill ja. pathological ventricular remodeling: therapies: part 2 of 2. circ j. 2013;128(9):1021-30. [Crossref]  [PubMed]  [PMC]
  38. Abboud a, januzzi jl. reverse cardiac remodeling and arnI therapy. curr Heart Fail rep. 2021;18(2):71-83. [Crossref]  [PubMed]
  39. Zhang n, wang Y, tse g, Korantzopoulos p, letsas Kp, Zhang Q, et al. effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. eur j prev cardiol. 2022;28(17):1961- 73. [Crossref]  [PubMed]